文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

SARS-CoV-2 关切变异株导致的 CD8 T 细胞免疫逃逸。

CD8 T-cell immune escape by SARS-CoV-2 variants of concern.

机构信息

Department of Obstetrics and Gynecology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Department of Radiation Oncology, Cedars Sinai Hospital, Los Angeles, Los Angeles, CA, United States.

出版信息

Front Immunol. 2022 Oct 27;13:962079. doi: 10.3389/fimmu.2022.962079. eCollection 2022.


DOI:10.3389/fimmu.2022.962079
PMID:36389664
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9647062/
Abstract

Despite the efficacy of antiviral drug repositioning, convalescent plasma (CP), and the currently available vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the worldwide coronavirus disease 2019 (COVID-19) pandemic is still challenging because of the ongoing emergence of certain new SARS-CoV-2 strains known as variants of concern (VOCs). Mutations occurring within the viral genome, characterized by these new emerging VOCs, confer on them the ability to efficiently resist and escape natural and vaccine-induced humoral and cellular immune responses. Consequently, these VOCs have enhanced infectivity, increasing their stable spread in a given population with an important fatality rate. While the humoral immune escape process is well documented, the evasion mechanisms of VOCs from cellular immunity are not well elaborated. In this review, we discussed how SARS-CoV-2 VOCs adapt inside host cells and escape anti-COVID-19 cellular immunity, focusing on the effect of specific SARS-CoV-2 mutations in hampering the activation of CD8 T-cell immunity.

摘要

尽管抗病毒药物再利用、恢复期血浆 (CP) 和目前可用的针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的疫苗具有疗效,但由于某些新的 SARS-CoV-2 株不断出现,即所谓的关注变体 (VOCs),全球 2019 年冠状病毒病 (COVID-19) 大流行仍然具有挑战性。这些新出现的 VOC 中发生的病毒基因组内突变使它们能够有效地抵抗和逃避自然和疫苗诱导的体液和细胞免疫反应。因此,这些 VOC 具有更高的感染力,增加了它们在特定人群中的稳定传播,死亡率很高。虽然体液免疫逃逸过程已有详细记录,但 VOC 逃避细胞免疫的机制尚未详细阐述。在这篇综述中,我们讨论了 SARS-CoV-2 VOC 如何在宿主细胞内适应并逃避抗 COVID-19 细胞免疫,重点讨论了特定 SARS-CoV-2 突变在阻碍 CD8 T 细胞免疫激活方面的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d2/9647062/c633b17559e6/fimmu-13-962079-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d2/9647062/f1af476bba74/fimmu-13-962079-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d2/9647062/7633c4ddad63/fimmu-13-962079-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d2/9647062/648f9e80db61/fimmu-13-962079-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d2/9647062/c633b17559e6/fimmu-13-962079-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d2/9647062/f1af476bba74/fimmu-13-962079-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d2/9647062/7633c4ddad63/fimmu-13-962079-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d2/9647062/648f9e80db61/fimmu-13-962079-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d2/9647062/c633b17559e6/fimmu-13-962079-g004.jpg

相似文献

[1]
CD8 T-cell immune escape by SARS-CoV-2 variants of concern.

Front Immunol. 2022

[2]
Structural insights into immune escape at killer T cell epitope by SARS-CoV-2 Spike Y453F variants.

J Biol Chem. 2024-8

[3]
Cross-protection induced by highly conserved human B, CD4, and CD8 T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern.

Front Immunol. 2024-1-22

[4]
Humoral and cellular immunity against diverse SARS-CoV-2 variants.

J Genet Genomics. 2023-12

[5]
CD8 T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2.

Front Immunol. 2021

[6]
Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 T-Cell Epitopes Identified in COVID-19 Convalescent Individuals.

mBio. 2022-4-26

[7]
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?

J Virol. 2022-3-23

[8]
Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope.

Cell. 2022-8-4

[9]
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.

mSphere. 2021-8-25

[10]
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.

Int Rev Immunol. 2023

引用本文的文献

[1]
Harnessing cellular immunity for next-generation vaccines against respiratory viruses: mechanisms, platforms, and optimization strategies.

Front Immunol. 2025-8-13

[2]
Dysfunctional Senescent Herpes Simplex Virus-Specific CD57CD8 T Cells Are Associated with Symptomatic Recurrent Ocular Herpes in Humans.

Viruses. 2025-4-24

[3]
The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis.

Vaccines (Basel). 2025-3-30

[4]
The trend of phylogenetic and epitope variations of SARS-CoV-2 Omicron sub-lineages in Iran.

Front Microbiol. 2025-1-29

[5]
The role of inflammatory gene polymorphisms in severe COVID-19: a review.

Virol J. 2024-12-20

[6]
Features of Highly Homologous T-Cell Receptor Repertoire in the Immune Response to Mutations in Immunogenic Epitopes.

Int J Mol Sci. 2024-11-23

[7]
SARS-CoV-2 within-host population expansion, diversification and adaptation in zoo tigers, lions and hyenas.

bioRxiv. 2024-10-24

[8]
The molecular mechanisms of CD8 T cell responses to SARS-CoV-2 infection mediated by TCR-pMHC interactions.

Front Immunol. 2024

[9]
Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections.

J Inflamm Res. 2024-7-26

[10]
Changes in the Adaptive Cellular Repertoire after Infection with Different SARS-CoV-2 VOCs in a Cohort of Vaccinated Healthcare Workers.

Vaccines (Basel). 2024-2-23

本文引用的文献

[1]
PD-L1 Overexpression in the Lungs of Subjects Who Died from COVID-19: Are We on the Way to Understanding the Immune System Exhaustion Induced by SARS-CoV-2?

Crit Rev Eukaryot Gene Expr. 2022

[2]
T cell response in patients with COVID-19.

Blood Sci. 2020-7-25

[3]
Identification of promising CD8 and CD4 T cell epitopes for peptide vaccine formulation against SARS-CoV-2.

Arch Microbiol. 2022-4-5

[4]
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals.

Cell. 2022-3-31

[5]
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.

Science. 2022-5-6

[6]
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals.

Cell. 2022-3-17

[7]
SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron.

Front Immunol. 2022

[8]
In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape.

Infect Genet Evol. 2022-4

[9]
Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences.

BMC Genomics. 2022-2-11

[10]
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.

N Engl J Med. 2022-3-31

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索